Provided by Tiger Fintech (Singapore) Pte. Ltd.

Instil Bio, Inc.

32.89
+2.568.44%
Post-market: 32.52-0.3738-1.14%18:38 EDT
Volume:336.86K
Turnover:11.03M
Market Cap:215.76M
PE:-2.75
High:34.90
Open:31.26
Low:30.50
Close:30.33
Loading ...

Instil Bio Price Target Maintained With a $125.00/Share by HC Wainwright & Co.

Dow Jones
·
05 Jun

Instil Bio Positioned as a Promising Player in the PD-1/L1 x VEGF Market with Strong Buy Recommendation

TIPRANKS
·
05 Jun

Instil Bio Shares up 33.6% After Bristol Myers-BioNTech Cancer Drug Partnership

THOMSON REUTERS
·
02 Jun

Top Premarket Gainers

MT Newswires Live
·
02 Jun

Shares of Instil Bio up 41% Premarket After Bristol Myers-BioNTech Cancer Drug Partnership

THOMSON REUTERS
·
02 Jun

Instil Bio Announces Appointment of Jamie Freedman, M.d., Ph.d., as Chief Medical Officer

THOMSON REUTERS
·
02 Jun

Press Release: Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer

Dow Jones
·
02 Jun

Instil Bio Elects Director and Ratifies Auditor

TIPRANKS
·
29 May

Instil Bio Inc. Conducted Annual Stockholders Meeting

Reuters
·
29 May

Instil Bio Advances Phase 2 Trial in China

TIPRANKS
·
28 May

Instil Bio Announces Upcoming Phase 3 Trial of '2510 in Combination with Chemotherapy for First-Line NSCLC in China, Set to Begin Mid-2026

Reuters
·
28 May

Citizens JMP Reaffirms Their Hold Rating on Instil Bio (TIL)

TIPRANKS
·
27 May

Instil Bio price target raised to $125 from $105 at H.C. Wainwright

TIPRANKS
·
23 May

Instil Bio, Inc. : H.c. Wainwright Raises Target Price to $125 From $105

THOMSON REUTERS
·
23 May

Instil Bio Shares Jump on Trial Updates for Lung Cancer Treatment

Dow Jones
·
23 May

Instil Bio, ImmuneOnco Say Lung Cancer Drug `2510 Mid-Stage Trial Enrollment in China on Track for Q3

MT Newswires Live
·
22 May

Instil Bio Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
22 May

ADVISORY-Alerts incorrectly tagged to T Rowe Price Large-Cap Value Fund withdrawn

Reuters
·
22 May

Instil Bio Inc - US Phase 1B/2 Trial of '2510 to Start Before End of 2025

THOMSON REUTERS
·
22 May

Immuneonco Biopharmaceuticals Announces New Clinical Trial Updates for IMM2510/AXN-2510 in First-Line NSCLC Treatment

Reuters
·
22 May